Compare INTU & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTU | BSX |
|---|---|---|
| Founded | 1983 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.9B | 137.8B |
| IPO Year | 1993 | 1992 |
| Metric | INTU | BSX |
|---|---|---|
| Price | $432.99 | $91.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 18 |
| Target Price | ★ $799.32 | $124.44 |
| AVG Volume (30 Days) | 2.9M | ★ 12.6M |
| Earning Date | 02-26-2026 | 02-04-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | 41.77 | ★ 54.68 |
| EPS | ★ 14.57 | 1.87 |
| Revenue | ★ $19,433,000,000.00 | $19,349,000,000.00 |
| Revenue This Year | $14.93 | $21.06 |
| Revenue Next Year | $12.49 | $11.43 |
| P/E Ratio | ★ $33.42 | $49.13 |
| Revenue Growth | 17.14 | ★ 21.61 |
| 52 Week Low | $486.62 | $85.98 |
| 52 Week High | $813.70 | $109.50 |
| Indicator | INTU | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 16.52 | 42.28 |
| Support Level | $491.72 | $91.45 |
| Resistance Level | $569.38 | $94.21 |
| Average True Range (ATR) | 20.22 | 2.23 |
| MACD | -9.80 | 0.05 |
| Stochastic Oscillator | 2.74 | 57.12 |
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small-to-midsize business accounting and self-serve tax filing in the US.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.